Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: HeyRainier who wrote (927)	5/12/1998 12:05:00 PM
From: Sylvester	Read Replies (1) \| Respond to of 4140

Rainer, See you at 25, hope I'm still young enough to enjoy it. What's new? My programmer resource spent a good part of his weekend explaining how programs pick stocks. Depending on the program 40 to 120 variables are measured against how these variables affect short and long term performance. Some sector funds may buy SNRS but insurance comapny funds would purchase none or very little because of no P/E ratio, or earning for that matter. Most of these funds have a lot of 401K dollars and the modeling they use to pick stocks stay away from volatility in general and anything with more than a 15 to 20% downside risk probably would not make the cut. No one programming team writes the entire program, and most certainly changes are made by the programmers dedicated to investment teams. This, in theory prevents programmers from knowing which stocks mutual are likely to target with any specificity. A medical director is not forbidden by the SEC from having an investment team look at a stock whose technology may benefit the company. For example, if (when) SNRS is FDA approved, healthcare company X may know that 30% of their subscribers are eligible to recieve a Sunrise laser procedure. This same data would appear in annual reports and NCQA filings so if we knew where to look, it's available to the public. If the "reasonable and customary" reimbursement for an approved hyperopia treatment were limited to $2000, Sunrise would have a distinct advantage over more expensive competitors. All this is why we, as individuals should buy this stock and has little to do with institutional buying practices. Too bad. Regarding your new support level. I'm sticking with what I have for the long term and don't anticipate any sells below 14 or buys unless we fall below 7. Thanks for your insights. Best Regards, Sylvester